Substituted oxazolidinone derivatives
This invention relates to novel compounds that are substituted oxazolidinones derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel oxazolidinones compounds that are derivatives of rivaroxaban. The invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and condition that are beneficially treated by administering a selective inhibitor of factor Xa, such as rivaroxaban.
1. A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
each of X 1a , X 1b , X 2a , X 2b , X 3a , and X 3b is deuterium; and Y 1a , and Y 1b are the same and are selected from hydrogen and deuterium.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y 1a and Y 1b are simultaneously hydrogen.
3. The compound of claim 1 or 2 , or a pharmaceutically acceptable salt thereof, wherein any atom not designated as deuterium is present at its natural isotopic abundance.
4. A pyrogen-free composition comprising a compound of claim 1 ,
or a pharmaceutically acceptable salt thereof,
and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4 , further comprising a therapeutic agent useful in the treatment of a disease or condition selected from pulmonary embolism, stroke, thromboembolism, deep venous thrombosis, thrombosis, myocardial infarction, acute coronary syndrome, disorders of coagulation, microangiopathy and thrombocytopenic purpura.
6. The pharmaceutical composition of claim 5 , wherein the therapeutic agent is aspirin.